市場調査レポート

西欧のコンパニオン診断市場

Western European Companion Diagnostics Market

発行 Frost & Sullivan 商品コード 304537
出版日 ページ情報 英文 164 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
西欧のコンパニオン診断市場 Western European Companion Diagnostics Market
出版日: 2014年05月23日 ページ情報: 英文 164 Pages
概要

当レポートでは、西欧のコンパニオン診断市場について調査し、がん関連セグメントの議論、がん・疾患タイプ別のテスト数の予測、各国における医療費償還経路の分析、規制状況の分析などを提供しています。

当レポートは、以下の疑問にお答えいたします。

  • 主な市場参入企業は?欧州市場において市場参入企業の成長はどのように戦略化されているか?
  • 現在、コンパニオン診断で用いられている製品分野は?
  • コンパニオン診断市場の本質を支えるビジネスモデルは?
  • 欧州のコンパニオン診断情勢に存在する主な課題は?
  • 時間の経過と共に市場の構造はどう変化するか?買収の時は熟しているか?
  • 現在の規制団体はどれだけ支援しているか?さまざまな地域で彼らが果たす役割は?

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場背景
  • 市場区分
  • 全体的な市場展望
  • 将来における医療動向の定義

第3章 欧州の規制概要

  • 規制概要:欧州
  • 欧州における将来のIVD規制
  • EMAの役割
  • 医薬品ラベルはEMAによるバイオマーカー検査を必要とする
  • FDA・CEマーキングの比較
  • 米国・欧州・中国の比較分析
  • 世界の規制展望

第4章 競合プレイブック

  • 新たな市場機会
  • 現在の市場参入企業の戦略議論
  • アンメットニーズの議論

第5章 促進因子・阻害因子:コンパニオン診断市場全体

  • 市場成長促進因子
  • 市場成長阻害因子
  • 主要動向の市場影響

第6章 予測・動向:コンパニオン診断市場全体

  • 測定
  • 欧州のコンパニオン診断市場の概要
  • 重要な市場特徴
  • 予測の前提条件
  • コンパニオン診断市場全体:収益予測
  • コンパニオン診断市場全体:疾患別の収益予測
  • 収益予測の議論
  • PEST分析

第7章 乳がん検査

  • 乳がん検査の収益予測
  • 乳がん検査の収益予測の議論

第8章 肺がん検査

第9章 結腸直腸がん・その他のがんの検査

第10章 感染症・CNS・心臓血管検査

第11章 競合環境

  • 競合環境
  • 製品分析
  • 主な競合企業
  • 市場シェア:ティア別
  • 合併・買収・提携評価
  • コンパニオン診断のパートナー
  • コンパニオン診断提携の治療分野
  • コンパニオン診断提携の種類
  • コンパニオン診断提携の世界的リーチ

第12章 欧州の医療費償還情勢

  • イントロダクション
  • 医療費償還システムの概要
  • 西欧全体にわたるCDx(コンパニオン診断)普及

第13章 ドイツ:医療費償還概要

  • 個別化医療の概要
  • 医療費償還の概要

第14章 フランス:医療費償還概要

  • 個別化医療の概要
  • 医療費償還の概要

第15章 英国:医療費償還概要

  • 個別化医療の概要
  • 医療費償還の概要

第16章 イタリア:医療費償還概要

  • 個別化医療の概要
  • 医療費償還の概要

第17章 スペイン:医療費償還概要

  • 個別化医療の概要
  • 医療支払い制度
  • 価格・医療費償還

第18章 スカンジナビア諸国:医療費償還概要

  • 個別化医療の概要
  • 医療費償還の概要

第19章 ベネルクス諸国:医療費償還概要

  • ベネルクス諸国:個別化医療の概要
  • オランダ:個別化医療の概要
  • オランダ:医療費償還の概要
  • ベルギー:個別化医療の概要
  • ベルギー:医療費償還の概要

第20章 結論

  • 結論:3大予測
  • 免責事項

第21章 付録

目次
Product Code: NCF9-52

Regulatory Hurdles and LDTs Stall the Global and European Market for Companion Diagnostics

The research service aims to give a global outlook of the companion diagnostic market landscape, with a specific focus on Western European countries. The segments related to oncology discussed in this study include breast cancer, lung cancer, colorectal cancer and other cancers, and non-oncology related infectious disease, CNS, and cardiovascular. The forecasts are based on test volumes for these cancers and disease types. Effective analysis of the reimbursement pathway in Germany, the United Kingdom, France, Italy, Spain, Scandinavia, and Benelux, coupled with regulatory approval in Europe, is discussed. A comparative assessment of regulatory scenarios has been performed to assess easy-target markets.

Key Questions This Study Will Answer

  • Who are the key market participants? How are they strategizing their growth in the European market?
  • In what current product areas are companion diagnostics being used? Which disease area is expected to experience the most growth in the future?
  • What are the different business models that exist and support the nature of the companion diagnostics market?
  • What are the key challenges that exist in the European companion diagnostics landscape?
  • How will the structure of the market change over time? Is it ripe for acquisitions?
  • How supportive are the current regulatory bodies? What impacts do they have in various regions?

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Key Findings
  • 2. Key Findings (continued)
  • 3. Scope and Segmentation
  • 4. Key Questions This Study Will Answer
  • 5. Measurements
  • 6. CEO's Perspective
  • 7. Key Companies to Watch
  • 8. Executive Summary-3 Big Predictions

2. MARKET OVERVIEW

Market Overview

  • 1. Market Background
  • 2. Market Background (continued)
  • 3. Market Background (continued)
  • 4. Market Background (continued)
  • 5. Market Segmentation
  • 6. Overall Market Perspective
  • 7. Defining Healthcare Trends in the Future

3. EUROPEAN REGULATORY OVERVIEW

European Regulatory Overview

  • 1. Regulatory Overview-Europe
  • 2. Regulatory Overview-Europe (continued)
  • 3. Future IVD Regulation in Europe
  • 4. Role of EMA
  • 5. Drug Labels Requiring Biomarker Testing by the EMA
  • 6. Comparison of FDA and CE Marking
  • 7. Comparative Analysis of the United States, Europe, and China
  • 8. Global Regulatory Outlook

4. COMPETITIVE PLAYBOOK

Competitive Playbook

  • 1. New Market Opportunities
  • 2. New Market Opportunities (continued)
  • 3. New Market Opportunities (continued)
  • 4. Current Participant Strategies Discussion
  • 5. Current Participant Strategies Discussion (continued)
  • 6. Unmet Needs Discussion
  • 7. Unmet Needs Discussion (continued)

5. DRIVERS AND RESTRAINTS-TOTAL COMPANION DIAGNOSTICS MARKET

Drivers and Restraints-Total Companion Diagnostics Market

  • 1. Market Drivers
  • 2. Market Restraints
  • 3. Market Impact of Top Trends

6. FORECASTS AND TRENDS-TOTAL COMPANION DIAGNOSTICS MARKET

Forecasts and Trends-Total Companion Diagnostics Market

  • 1. Measurements
  • 2. Snapshot of the European Companion Diagnostics Market
  • 3. Important Market Characteristics
  • 4. Forecast Assumptions
  • 5. Total Companion Diagnostics Market-Revenue Forecast
  • 6. Total Companion Diagnostics Market-Revenue Forecast by Disease Focus
  • 7. Revenue Forecast Discussion
  • 8. Revenue Forecast Discussion (continued)
  • 9. PEST Analysis
  • 10. PEST Analysis (continued)

7. BREAST CANCER TESTING

Breast Cancer Testing

  • 1. Revenue Forecast for Breast Cancer Testing
  • 2. Revenue Forecast for Breast Cancer Testing Discussion

8. LUNG CANCER TESTING

Lung Cancer Testing

  • 1. Revenue Forecast for Lung Cancer Testing
  • 2. Revenue Forecast for Lung Cancer Testing Discussion

9. COLORECTAL CANCER AND OTHER CANCERS TESTING

Colorectal Cancer and Other Cancers Testing

  • 1. Revenue Forecast for Colorectal Cancer Testing
  • 2. Revenue Forecast for Other Cancers Testing
  • 3. Revenue Forecast for Colorectal Cancer and Other Cancers Testing Discussion

10. INFECTIOUS DISEASE, CNS, AND CARDIOVASCULAR TESTING

Infectious Disease, CNS, and Cardiovascular Testing

  • 1. Revenue Forecast for Infectious Disease, CNS, and Cardiovascular Testing
  • 2. Revenue Forecast for Infectious Disease, CNS, and Cardiovascular Testing Discussion
  • 3. Revenue Forecast Discussion
  • 4. Revenue Forecast Discussion (continued)

11. COMPETITIVE ENVIRONMENT

Competitive Environment

  • 1. Competitive Environment
  • 2. Competitive Environment (continued)
  • 3. Product Analysis
  • 4. Product Analysis (continued)
  • 5. Top Competitors
  • 6. Top Competitors (continued)
  • 7. Market Share by Tier
  • 8. Market Share by Tier (continued)
  • 9. Merger, Acquisition, and Partnership Assessment
  • 10. Merger, Acquisition, and Partnership Assessment (continued)
  • 11. Companion Diagnostic Partners
  • 12. Companion Diagnostic Partners (continued)
  • 13. Therapy Areas for Companion Diagnostic Partnerships
  • 14. Types of Companion Diagnostic Partnerships
  • 15. Global Reach of Companion Diagnostic Partnership

12. EUROPEAN REIMBURSEMENT LANDSCAPE

European Reimbursement Landscape

  • 1. Introduction
  • 2. Reimbursement Systems Overview
  • 3. CDx Penetration Across Western Europe

13. GERMANY-REIMBURSEMENT OVERVIEW

Germany-Reimbursement Overview

  • 1. Germany-Personalized Medicine Overview
  • 2. Germany-Personalized Medicine Overview (continued)
  • 3. Germany-Overview of Reimbursement

14. FRANCE-REIMBURSEMENT OVERVIEW

France-Reimbursement Overview

  • 1. France-Personalized Medicine Overview
  • 2. France-Personalized Medicine Overview (continued)
  • 3. France-Overview of Reimbursement
  • 4. France-Overview of Reimbursement (continued)

15. THE UNITED KINGDOM-REIMBURSEMENT OVERVIEW

The United Kingdom-Reimbursement Overview

  • 1. The United Kingdom-Personalized Medicine Overview
  • 2. The United Kingdom-Personalized Medicine Overview (continued)
  • 3. The United Kingdom-Overview of Reimbursement

16. ITALY-REIMBURSEMENT OVERVIEW

Italy-Reimbursement Overview

  • 1. Italy-Personalized Medicine Overview
  • 2. Italy-Personalized Medicine Overview (continued)
  • 3. Italy-Personalized Medicine Overview (continued)
  • 4. Italy-Overview of Reimbursement
  • 5. Italy-Overview of Reimbursement (continued)

17. SPAIN-REIMBURSEMENT OVERVIEW

Spain-Reimbursement Overview

  • 1. Spain-Personalized Medicine Overview
  • 2. Spain-Healthcare Payment System
  • 3. Spain-Pricing and Reimbursement
  • 4. Spain-Pricing and Reimbursement (continued)

18. SCANDINAVIA-REIMBURSEMENT OVERVIEW

Scandinavia-Reimbursement Overview

  • 1. Scandinavia-Personalized Medicine Overview
  • 2. Scandinavia-Personalized Medicine Overview (continued)
  • 3. Scandinavia-Reimbursement Overview
  • 4. Scandinavia-Reimbursement Overview (continued)

19. BENELUX-REIMBURSEMENT OVERVIEW

Benelux-Reimbursement Overview

  • 1. Benelux-Personalized Medicine Overview
  • 2. The Netherlands-Personalized Medicine Overview
  • 3. The Netherlands-Reimbursement Overview
  • 4. The Netherlands-Reimbursement Overview (continued)
  • 5. Belgium-Personalized Medicine Overview
  • 6. Belgium-Reimbursement Overview
  • 7. Belgium-Reimbursement Overview (continued)

20. THE LAST WORD

The Last Word

  • 1. The Last Word-3 Big Predictions
  • 2. The Last Word-Discussion
  • 3. The Last Word-Discussion (continued)
  • 4. The Last Word-Discussion (continued)
  • 5. The Last Word-Discussion (continued)
  • 6. The Last Word-Discussion (continued)
  • 7. Legal Disclaimer

21. APPENDIX

Appendix

  • 1. Europe-Drivers Explained
  • 2. Europe-Drivers Explained (continued)
  • 3. Europe-Drivers Explained (continued)
  • 4. Europe-Restraints Explained
  • 5. Europe-Restraints Explained (continued)
  • 6. Europe-Restraints Explained (continued)
  • 7. Europe-Restraints Explained (continued)
  • 8. Europe-Restraints Explained (continued)
  • 9. Europe-Restraints Explained (continued)
  • 10. Europe-Restraints Explained (continued)
  • 11. Europe-Restraints Explained (continued)
  • 12. Decision Support Database
  • 13. Decision Support Database (continued)
  • 14. Decision Support Database (continued)
  • 15. Decision Support Database (continued)
  • 16. Decision Support Database (continued)
  • 17. Associated Multimedia
  • 18. Methodology
  • 19. Learn More-Next Steps
Back to Top